ReviewCurrent opinion in immunology2013
Innate immune mechanisms in vitiligo: danger from within.
Review in Current opinion in immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 1 synthesis or guideline pooled it, 215 citations in OpenAlex.
- Interventions for vitiligo.The Cochrane database of systematic reviews · 2015Pooled it
- Efficacy and safety of fire needle therapy in treating non-segmental stable vitiligo: A randomized self-controlled clinical trial.Journal of cosmetic dermatology · 2024Trial
- Interleukin 32 Exacerbates Vitiligo by Promoting Inflammation and Oxidative Stress-induced Injury in Melanocytes.Inflammation · 2026Article
- Association of Serum Interleukin-17 Levels With Vitiligo: A Pilot Cross-Sectional Comparative Study.Cureus · 2026Article
- Molecular Pathogenesis of Vitiligo: Emerging Roles of Epigenetic Regulation.Biomolecules & therapeutics · 2026Review
- A Multifaceted Holistic Review of the Literature on Scar Dermatoses.International wound journal · 2026Review
- Neuropeptide Y drives vitiligo progression via NPYR-mediated NF-κB activation: a novel therapeutic target.Scientific reports · 2026Article
- The immunology of vitiligo.Nature reviews. Immunology · 2026Review
- Hydroxypropyl-β-cyclodextrin co-delivery hydrogel of crisaborole and curcumin for combinational antioxidant/anti-inflammatory therapy of vitiligo.Materials today. Bio · 2026Article
- Pathogenesis of Vitiligo: Integrating Immune and Non-Immune Cell Crosstalk.The Journal of dermatology · 2026Review
- Harnessing the Anti-Inflammatory Effects of Perinatal Tissue Derived Therapies for the Treatment of Inflammatory Skin Diseases: A Comprehensive Review.Stem cell reviews and reports · 2025Review
- Updates on the Role of Innate Immunity's Pattern Recognition Receptors in Vitiligo Pathogenesis and Therapeutic Potential.Clinical, cosmetic and investigational dermatology · 2025Review
- Innate immune activation in vitiligo: mechanisms and pathophysiological implications.Frontiers in immunology · 2025Review
- Vitiligo: From mechanisms of disease to treatable pathways.Skin health and disease · 2024Review
- Up-and-Coming Drugs for the Treatment of Vitiligo.Annals of dermatology · 2024Review
- Protocol for a systematic review and meta-analysis on Janus kinase inhibitors in the management of vitiligo.Systematic reviews · 2024Article
- Pathogenesis of Alopecia Areata and Vitiligo: Commonalities and Differences.International journal of molecular sciences · 2024Review
- Association between miR-202, miR-211, and miR-1238 gene polymorphisms and risk of vitiligo.Archives of dermatological research · 2024Article
- EGR1 Mediated Reduction of Fibroblast Secreted-TGF-β1 Exacerbated CD8Inflammation · 2024Article
- Endoplasmic Reticulum Dysfunction: An Emerging Mechanism of Vitiligo Pathogenesis.Clinical, cosmetic and investigational dermatology · 2024Review
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Vitiligo is an autoimmune disease of the skin in which melanocytes are destroyed by antigen-specific T cells, resulting in patchy depigmentation. Although adaptive immunity plays a clear role in disease progression, initiating factors are largely unknown. Many studies report that cellular stress pathways are dysregulated in melanocytes from vitiligo patients, suggesting that melanocyte-intrinsic defects participate in disease pathogenesis. Recent studies reveal that melanocyte stress generates damage-associated molecular patterns that activate innate immunity, thus connecting stress to organ-specific inflammation. Genetic studies in vitiligo support a role for stress, innate immunity, and adaptive mechanisms. Here, we discuss advances in the field that highlight how cellular stress, endogenous danger signals, and innate immune activation promote the onset of vitiligo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.